Clinical Trials


LACOG 0211 - ALK


A clinical and epidemiologic study of EML4-ALK and other ALK fusions genes in lung cancer patients in Latin American.

Primary Objective

To estimate the prevalence of EML4-ALK fusio gene in Latin American in patients with non squamous-cell lung carcinoma.


This is a retrospective study to explore the prevalence of a specific biomarker in a sequential unselected cohort of non squamous NSCLC patients from Latin American cancer treatment institutions.

Sample size: 1154

LACOG Study Coordinators: Carlos Gil, Clarissa Baldotto, Carlos Barrios

Status: Recruiting

Sponsor: INCA 

LACOG 0211 - ALK


Phone: 55 51 3384 5334